Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials

被引：116

作者：

Vetvicka, Vaclav ^{[1
]}

Vannucci, Luca ^{[2
]}

Sima, Petr ^{[2
]}

Richter, Josef ^{[3
]}

机构：

[1] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA

[2] Inst Microbiol, Dept Immunol, Prague 14220, Czech Republic

[3] Zdravotni Ustav Sidlem Usti Nad Labem, Usti Nad Labem 40001, Czech Republic

来源：

MOLECULES | 2019年 / 24卷 / 07期

关键词：

glucan; drug; immunity; food; supplement; infection; mushrooms; PLEUROTUS-OSTREATUS; INNATE IMMUNITY; RESPIRATORY-INFECTIONS; OAT-BRAN; RESISTANCE; RESPONSES; MICE; NUTRITION; CYTOKINES; ANTITUMOR;

D O I：

10.3390/molecules24071251

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Glucans are part of a group of biologically active natural molecules and are steadily gaining strong attention not only as an important food supplement, but also as an immunostimulant and potential drug. This paper represents an up-to-date review of glucans (beta-1,3-glucans) and their role in various immune reactions and the treatment of cancer. With more than 80 clinical trials evaluating their biological effects, the question is not if glucans will move from food supplement to widely accepted drug, but how soon.

引用

页数：17

共 50 条

[21] From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
Heemskerk, J
Tobin, AJ
Ravina, B
NATURE NEUROSCIENCE, 2002, 5 (Suppl 11) : 1027 - 1029
[22] Beta-Glucan from Oats
不详
ERNAHRUNGS UMSCHAU, 2012, 59 (04): : 242 - 243
[23] WHAT DOES LABORATORY WORKER EXPECT FROM CLINICAL TRIALS
BLOCH, H
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1963, 4 (03) : 390 - &
[24] Role of Chinese herbal medicines: from laboratory to clinical trials
Gohel, M. D. I.
Ng, A. C. F.
Wong, S. S. C.
BJU INTERNATIONAL, 2008, 101 : 17 - 17
[25] Navigating Oncology Clinical Trials: From Drug Development to
Bourgeois, John
Goodman, Monica S.
Braga, Catherine
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2025, 29 (01) : 91 - 95
[26] Learning disease relationships from clinical drug trials
Haslam, Bryan
Perez-Breva, Luis
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2017, 24 (01) : 13 - 23
[27] Analysis of Drug Safety Data From Clinical Trials
Andrzej Czarnecki
Katarzyna Zalewska
Drug information journal : DIJ / Drug Information Association, 2002, 36 (1): : 157 - 162
[28] Analysis of drug safety data from clinical trials
Czarnecki, A
Zalewska, K
DRUG INFORMATION JOURNAL, 2002, 36 (01): : 157 - 162
[29] Isolation of Beta-Glucan from Yeast and its Use as a Dietary Supplement for Low-fat Yoghurt Manufacturing
Vyrova, D. V.
Selezneva, I. S.
PHYSICS, TECHNOLOGIES AND INNOVATION (PTI-2019), 2019, 2174
[30] SEX AND PERMANENT DRUG DISCONTINUATION IN CLINICAL TRIALS: INSIGHTS FROM THE TIMI TRIALS
Lau, Emily
Braunwald, Eugene
Morrow, David A.
Giugliano, Robert
Antman, Elliott M.
Gibson, C. Michael
Scirica, Benjamin M.
Bohula, Erin Ann
Bhatt, Deepak
Cannon, Christopher P.
Im, KyungAh
Guo, Jianping
Sabatine, Marc Steven
O'Donoghue, Michelle
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 3506 - 3506

← 1 2 3 4 5 →